" Cell-Based Assays - Latest Advances, Challenges and Solutions from Internationally Recognized Key Opinion Leaders"
Understanding the Challenges of Cell-Based Assays Applications in Cellular Immunogenicity (NAb Assays), Cell Therapy (Cellular Kinetics & PK CAR T Cell Clinical Trials), Biomarkers (Receptor Occupancy & Target Engagement) and Vaccines (Cell-Mediated Immunity/Functional Assays); Recent Approaches ELISpot & FluoroSpot Development/Validation and Technology Advancements; Innovative Approaches for Overcoming the Issue in Isolation of Peripheral Blood Mononuclear Cells (PBMCs); Advancements in Liquid Biopsies ctDNA Biomarkers for Disease Monitoring; Regulatory Expectation on ELISpot Assays for Submitted Studies; Newest Innovations in Spectral Cytometry, Mass Cytometry, and Imagine Cytometry; Novel Applications of Artificial Intelligence (AI)/Machine Learning (ML) for High Parameter Cytometry Applications and Data management; Current Status of Single-Cell Assays for High Dimensional Cytometry in Clinical Trials; AND LASTLY WRIB Traditional KOL Industry/Regulators Focused and Highly Interactive Panel Discussions on Discovery/Regulated Cell-Based Assays (Cytometry, ELISpot, In-vitro) Applications and Recent Controversial Issues
Session 1: High Dimensional Flow Cytometry: Implementing AI/ML/Automation, Ensuring Quality, Improving Manual Processing & Data/Gating Analysis
Session 2: Biomarker & Cell Therapy: Innovative Flow Cytometry Applications for RO/TE & CAR-T PK-like Assays
Session 3: Immunogenicity & Oncology: Advanced Applications of Cell-Based Assays and Flow Cytometry
Session 4: Breaking through Complex Panels & Technology Barriers to Enable Advanced HD Flow/Mass Cytometry Applications
Session 5: 2024 White Paper in Bioanalysis
-
2024 White Paper on Cell-Based Assays - Latest Advances, Challenges and Solutions from Internationally Recognized Key Opinion Leaders
Consensus & Conclusions on Cell-Based Assays - Latest Advances, Challenges and Solutions from Internationally Recognized Key Opinion Leaders for 2024 White Paper
